Viral RNA Quantification for Replication Competent Virus Detection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for detecting replication competent retroviruses in therapeutic compositions are either time-consuming or prone to false positives, necessitating the development of a more efficient and accurate approach to ensure the absence of replication competent virus in samples intended for administration.

Innovation Solution

The method involves determining the level of viral RNA in a biological sample by comparing it to reference values, using real-time PCR techniques to assess the presence or absence of specific viral genes such as env, gag, pol, or rev, which are indicative of replication competency, thereby quickly and accurately detecting the presence of replication competent retroviruses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Loss of time

If existing methods are used to verify the absence of replication competent virus, then the detection can be performed, but the process is overly time consuming

Engineering Contradiction:
Improvedetection timeVSAvoiddetection accuracy
Core Design Contradiction:
Loss of timeVSReliability

Solution Approach 1:

The patent changes the detection parameter from traditional cell-based assays to direct viral RNA quantification using qPCR. This parameter change enables rapid detection within hours while maintaining high reliability through specific viral gene targeting, resolving the time-consuming nature of existing methods without sacrificing accuracy

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent replaces complex cell-based mechanical assay systems with a molecular biology approach using qPCR. This substitution eliminates the need for cell culture, infection cycles, and phenotypic readouts, thereby dramatically reducing detection time while improving reliability through direct molecular detection

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If existing methods are used to detect replication competent virus, then detection can be performed, but false positive results occur

Engineering Contradiction:
Improvedetection accuracyVSAvoiddetection time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent extracts and detects only specific viral RNA sequences that are characteristic of replication competent virus. By targeting specific viral genes and using quantitative analysis, the method eliminates false positives caused by non-specific binding or background noise in traditional assays, thereby improving reliability without significant time loss

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent incorporates reference controls and threshold-based analysis in the qPCR methodology. The comparison of viral RNA levels against established thresholds and control samples provides immediate feedback on detection validity, allowing rapid identification of true positives while eliminating false positives through quantitative validation

Inventive Principle:
Principle #23Feedback

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for rapid and sensitive detection of replication competent viruses, reducing the risk of false positives and negatives, and ensuring the safety of therapeutic compositions by confirming the absence of replication competent retroviruses in a timely manner.

Implementation Method 1

using real-time PCR techniques to assess the presence or absence of specific viral genes

Methodology Applied
Scientific EffectPolymerase chain reaction:

Data Source

PatentUS11421287B2Methods for assessing the presence or absence of replication competent virus
Publication Date: 2022.08.23 JUNO THERAPEUTICS INC

AI summary

Provided are methods of detecting replication competent retrovirus in a sample containing a cell transduced with a viral vector particle encoding a recombinant and/or heterologous molecule, e.g., heterologous gene product. The methods may include assessing transcription of one or more target genes, such as viral genes, that are expressed in a retrovirus but not expressed in the viral vector particle. Replication competent retrovirus may be determined to be present if the levels of RNA of the one or more target genes is higher than a reference value, which can be measured directly or indirectly, including from a positive control sample containing RNA from the respective target gene at a known level and/or at or above the limit of detection of the assay.